Cytidine

Cytidine is starting material of Molnupiravir. Molnupiravir (MK-4482/EIDD-2801) is an experimental oral antiviral drug originally developed to treat influenza. MK-4482/EIDD-2801 consists of the nucleoside analogue N4-hydroxycytidine (NHC). Molnupiravir has been evaluated against coronaviruses (CoVs), including SARS-1, MERS-CoV, and SARS-CoV-2.

On January 25, 2021, Merck stated Molnupiravir is currently being evaluated in Phase 2/3 clinical trials in both the hospital and out-patient settings. The primary completion date for the Phase 2/3 studies is May 2021. The company anticipates initial efficacy data in the first quarter of 2021, which Merck plans to share publicly if clinically meaningful.

ROS of Molnupiravir, Cytidine as starting material.

Haorui, a leading Cytidine CAS#65-46-3 manufacturer, our Cytidine supplying offers for your requirements of RND, evaluation, pilots, and commercial, as a pharmaceutical intermediates supplier, we provide supportive technical package for evaluation.